The assessment and therapy of autoimmune diseases are poorly studied. This is in part due to the rarity and heterogeneity of many of these disorders as well as the uncertainty of their pathogeneses. We are focusing on the idiopathic inflammatory myopathies (IIM) as prototypic autoimmune diseases from which we hope that principles learned in these disorders may be applied generally to other autoimmune diseases. The IIM are orphan diseases, with an estimated incidence of only 10 cases per million per year, but yet they are associated with substantial lifelong morbidity and mortality. Their treatment is unsatisfactory in many cases and drug efficacy evaluation is hampered by the lack of reliable and standardized measures of disease outcome. Consequently, drug safety and efficacy data tend to be from small-uncontrolled non-comparable clinical trials. No agents are currently licensed for the treatment of the IIM and few have been studied in randomized controlled clinical trials.
The aims of this project are to standardize the conduct and reporting of clinical studies of autoimmune diseases and to coordinate international efforts in this area in order to develop improved therapies. Because of the lack of consensus on how to best measure disease in the myositis syndromes, and to enhance recruitment of patients for other studies, new disease assessment tools are being developed and validated to apply to all forms of myositis in both adults and children. We have organized a collaborative group of over 100 adult and pediatric specialists with special interest in myositis, known as the International Myositis Assessment and Clinical Studies Group (IMACS) to assist in this project. The goals of IMACS are to develop and validate sensitive and efficient disease activity and damage measurement tools, define improvement criteria for use in clinical trials, develop consensus on a number of clinical trial design parameters and to assist in the conduct of multicenter clinical trials. Achieving these goals should enhance the consistency by which clinical trials are performed, improve the capacity to compare different treatments, and encourage development of promising novel therapeutic agents. Therapeutic studies of novel biologic agents are in progress and others are being planned to utilize these outcome measures in prospective trials.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Intramural Research (Z01)
Project #
1Z01ES101081-03
Application #
7007522
Study Section
(DIR)
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
2004
Total Cost
Indirect Cost
Name
U.S. National Inst of Environ Hlth Scis
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Kishi, Takayuki; Bayat, Nastaran; Ward, Michael M et al. (2018) Medications received by patients with juvenile dermatomyositis. Semin Arthritis Rheum 48:513-522
Rider, Lisa G; Dankó, Katalin; Miller, Frederick W (2014) Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research. Curr Opin Rheumatol 26:724-41
Ruperto, Nicolino; Pistorio, Angela; Ravelli, Angelo et al. (2010) The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken) 62:1533-41
Lachenbruch, Peter A; Miller, Frederick W; Rider, Lisa G (2009) On Determining the Effects of Therapy on Disease Damage in Non- randomized Studies with Multiple Treatments: A study of Juvenile Myositis. Commun Stat Theory Methods 38:3268-3281
Dugan, Elizabeth M; Huber, Adam M; Miller, Frederick W et al. (2009) Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J 15:2
Harris-Love, M O; Shrader, J A; Koziol, D et al. (2009) Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology (Oxford) 48:134-9
Lachenbruch, Peter A; Miller, Frederick W; Rider, Lisa G (2007) Developing international consensus on measures of improvement for patients with myositis. Stat Methods Med Res 16:51-64
Huber, A M; Dugan, E M; Lachenbruch, P A et al. (2007) The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) 46:1606-11
Chung, Y-L; Rider, L G; Bell, J D et al. (2005) Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. Arthritis Rheum 53:565-70
Oddis, Chester V; Rider, Lisa G; Reed, Ann M et al. (2005) International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 52:2607-15

Showing the most recent 10 out of 22 publications